Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Breast cancer highlights from ESMO 2019

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Breast cancer highlights from ESMO 2019 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
2 Oct 2019

ClarIDHy: Targeted therapy ivosidenib for advanced cholangiocarcinoma

Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City, USA
ClarIDHy: Targeted therapy ivosidenib for advanced cholangiocarcinoma ( Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City, USA )
30 Sep 2019

Comment: Targeted therapy ivosidenib in cholangiocarcinoma

Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK
Comment: Targeted therapy ivosidenib in cholangiocarcinoma ( Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK )
30 Sep 2019

Targeted therapy ivosidenib shows clinical benefit in cholangiocarcinoma

Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City, USA
Targeted therapy ivosidenib shows clinical benefit in cholangiocarcinoma ( Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City, USA )
30 Sep 2019

Comment: PARP inhibitors for advanced prostate cancer

Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain
Comment: PARP inhibitors for advanced prostate cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )
30 Sep 2019

PARP inhibitor olaparib slows progression of advanced prostate cancer

Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago, USA
PARP inhibitor olaparib slows progression of advanced prostate cancer ( Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago, USA )
30 Sep 2019

BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer

Prof Josep Tabernero - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain
BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer ( Prof Josep Tabernero - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain )
30 Sep 2019

Comment: Veliparib with carboplatin and paclitaxel in advanced gBRCA-positive breast cancers

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Comment: Veliparib with carboplatin and paclitaxel in advanced gBRCA-positive breast cancers ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
29 Sep 2019

Immunotherapy added to chemotherapy improves pathological complete response in early triple negative breast cancer

Prof Peter Schmid - St Bartholomew's Hospital London, London, UK
Immunotherapy added to chemotherapy improves pathological complete response in early triple negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )
29 Sep 2019

Comment: CDK4/6 inhibitors in advanced breast cancer

Prof Nadia Harbeck - University of Munich, Munich, Germany
Comment: CDK4/6 inhibitors in advanced breast cancer ( Prof Nadia Harbeck - University of Munich, Munich, Germany )
29 Sep 2019

CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-negative advanced breast cancer

Prof George Sledge - Stanford Health Care, Stanford, USA
CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-negative advanced breast cancer ( Prof George Sledge - Stanford Health Care, Stanford, USA )
29 Sep 2019

CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postmenopausal HR-positive HER2-negative breast cancer

Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, California
CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postmenopausal HR-positive HER2-negative breast cancer ( Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, California )
29 Sep 2019